Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction

Shigeo Takemura, Hiromu Kondo, Shunsuke Watanabe, Kazuhiro Sako, Ken Ichi Ogawara, Kazutaka Higaki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of this study was to find out polymeric compounds that can inhibit the interaction between YM466, a novel anticoagulant, and bile to improve its oral bioavailability. In vitro ultrafiltration method using extract gall powder was useful to detect the formation of insoluble complex of YM466 with bile and also used to select a polymer that can inhibit the interaction between YM466 and bile. The in vitro studies revealed that aminoalkylmethacrylate (AAM) copolymer E, a polymethacrylate, dose-dependently inhibited the interaction between YM466 and bile and that this polymer could interact with bile salt, but not with YM466, possibly by electrostatic and/or hydrophobic interactions. The coadministration of AAM copolymer E with YM466 to rats dose-dependently increased the plasma concentration of YM466 and it was found that the oral dose of the polymer three times of YM466 (polymer to drug ratio in weight, P-D ratio, 3) significantly increased AUC0-1 h of YM466 to 2.6-fold of that of YM466 alone. Considering the condition of therapeutic use of YM466 and the maximum tolerated dose of the polymer, the formulation of P-D ratio 3 would be clinically practical and promising from the viewpoint of safety.

Original languageEnglish
Pages (from-to)3128-3135
Number of pages8
JournalJournal of Pharmaceutical Sciences
Volume102
Issue number9
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Drug Interactions
Bile
Biological Availability
Polymers
YM 60828
Maximum Tolerated Dose
Ultrafiltration
Therapeutic Uses
Bile Acids and Salts
Static Electricity
Hydrophobic and Hydrophilic Interactions
Powders
Anticoagulants
Safety
Weights and Measures

Keywords

  • Aminoalkylmethacrylate copolymer E
  • Bile
  • Bioavailability
  • Excipients
  • Intestinal absorption
  • Oral anticoagulant
  • Passive diffusion/transport
  • Solubility
  • YM466

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction. / Takemura, Shigeo; Kondo, Hiromu; Watanabe, Shunsuke; Sako, Kazuhiro; Ogawara, Ken Ichi; Higaki, Kazutaka.

In: Journal of Pharmaceutical Sciences, Vol. 102, No. 9, 09.2013, p. 3128-3135.

Research output: Contribution to journalArticle

Takemura, Shigeo ; Kondo, Hiromu ; Watanabe, Shunsuke ; Sako, Kazuhiro ; Ogawara, Ken Ichi ; Higaki, Kazutaka. / Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction. In: Journal of Pharmaceutical Sciences. 2013 ; Vol. 102, No. 9. pp. 3128-3135.
@article{8be6510824964ec48c7e3b1605372fa1,
title = "Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction",
abstract = "The aim of this study was to find out polymeric compounds that can inhibit the interaction between YM466, a novel anticoagulant, and bile to improve its oral bioavailability. In vitro ultrafiltration method using extract gall powder was useful to detect the formation of insoluble complex of YM466 with bile and also used to select a polymer that can inhibit the interaction between YM466 and bile. The in vitro studies revealed that aminoalkylmethacrylate (AAM) copolymer E, a polymethacrylate, dose-dependently inhibited the interaction between YM466 and bile and that this polymer could interact with bile salt, but not with YM466, possibly by electrostatic and/or hydrophobic interactions. The coadministration of AAM copolymer E with YM466 to rats dose-dependently increased the plasma concentration of YM466 and it was found that the oral dose of the polymer three times of YM466 (polymer to drug ratio in weight, P-D ratio, 3) significantly increased AUC0-1 h of YM466 to 2.6-fold of that of YM466 alone. Considering the condition of therapeutic use of YM466 and the maximum tolerated dose of the polymer, the formulation of P-D ratio 3 would be clinically practical and promising from the viewpoint of safety.",
keywords = "Aminoalkylmethacrylate copolymer E, Bile, Bioavailability, Excipients, Intestinal absorption, Oral anticoagulant, Passive diffusion/transport, Solubility, YM466",
author = "Shigeo Takemura and Hiromu Kondo and Shunsuke Watanabe and Kazuhiro Sako and Ogawara, {Ken Ichi} and Kazutaka Higaki",
year = "2013",
month = "9",
doi = "10.1002/jps.23484",
language = "English",
volume = "102",
pages = "3128--3135",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction

AU - Takemura, Shigeo

AU - Kondo, Hiromu

AU - Watanabe, Shunsuke

AU - Sako, Kazuhiro

AU - Ogawara, Ken Ichi

AU - Higaki, Kazutaka

PY - 2013/9

Y1 - 2013/9

N2 - The aim of this study was to find out polymeric compounds that can inhibit the interaction between YM466, a novel anticoagulant, and bile to improve its oral bioavailability. In vitro ultrafiltration method using extract gall powder was useful to detect the formation of insoluble complex of YM466 with bile and also used to select a polymer that can inhibit the interaction between YM466 and bile. The in vitro studies revealed that aminoalkylmethacrylate (AAM) copolymer E, a polymethacrylate, dose-dependently inhibited the interaction between YM466 and bile and that this polymer could interact with bile salt, but not with YM466, possibly by electrostatic and/or hydrophobic interactions. The coadministration of AAM copolymer E with YM466 to rats dose-dependently increased the plasma concentration of YM466 and it was found that the oral dose of the polymer three times of YM466 (polymer to drug ratio in weight, P-D ratio, 3) significantly increased AUC0-1 h of YM466 to 2.6-fold of that of YM466 alone. Considering the condition of therapeutic use of YM466 and the maximum tolerated dose of the polymer, the formulation of P-D ratio 3 would be clinically practical and promising from the viewpoint of safety.

AB - The aim of this study was to find out polymeric compounds that can inhibit the interaction between YM466, a novel anticoagulant, and bile to improve its oral bioavailability. In vitro ultrafiltration method using extract gall powder was useful to detect the formation of insoluble complex of YM466 with bile and also used to select a polymer that can inhibit the interaction between YM466 and bile. The in vitro studies revealed that aminoalkylmethacrylate (AAM) copolymer E, a polymethacrylate, dose-dependently inhibited the interaction between YM466 and bile and that this polymer could interact with bile salt, but not with YM466, possibly by electrostatic and/or hydrophobic interactions. The coadministration of AAM copolymer E with YM466 to rats dose-dependently increased the plasma concentration of YM466 and it was found that the oral dose of the polymer three times of YM466 (polymer to drug ratio in weight, P-D ratio, 3) significantly increased AUC0-1 h of YM466 to 2.6-fold of that of YM466 alone. Considering the condition of therapeutic use of YM466 and the maximum tolerated dose of the polymer, the formulation of P-D ratio 3 would be clinically practical and promising from the viewpoint of safety.

KW - Aminoalkylmethacrylate copolymer E

KW - Bile

KW - Bioavailability

KW - Excipients

KW - Intestinal absorption

KW - Oral anticoagulant

KW - Passive diffusion/transport

KW - Solubility

KW - YM466

UR - http://www.scopus.com/inward/record.url?scp=84881616270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881616270&partnerID=8YFLogxK

U2 - 10.1002/jps.23484

DO - 10.1002/jps.23484

M3 - Article

C2 - 23459999

AN - SCOPUS:84881616270

VL - 102

SP - 3128

EP - 3135

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 9

ER -